Kern W - Search Results

1

[Diagnostics and therapy of acute myeloid leukemia].

Kern W, Haferlach T, Schoch C, Hiddemann W. Kern W, et al. Dtsch Med Wochenschr. 2002 Oct 18;127(42):2208-13. doi: 10.1055/s-2002-34943. Dtsch Med Wochenschr. 2002. PMID: 12397550 German. No abstract available.

2

High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Kern W, Kurrle E, Vanek E. Kern W, et al. Klin Wochenschr. 1987 Aug 17;65(16):773-80. doi: 10.1007/BF01743253. Klin Wochenschr. 1987. PMID: 3477669

3

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W. Schleyer E, et al. Among authors: kern w. Leukemia. 1996 Apr;10(4):707-12. Leukemia. 1996. PMID: 8618451 Clinical Trial.

4

Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.

Hiddemann W, Schleyer E, Unterhalt M, Kern W, Büchner T. Hiddemann W, et al. Among authors: kern w. Ther Drug Monit. 1996 Aug;18(4):341-9. doi: 10.1097/00007691-199608000-00005. Ther Drug Monit. 1996. PMID: 8857548

5

Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.

Braess J, Kern W, Unterhalt M, Kaufmann CC, Ramsauer B, Schüssler M, Kaeser-Fröhlich A, Hiddemann W, Schleyer E. Braess J, et al. Among authors: kern w. Ann Hematol. 1996 Oct;73(4):201-4. doi: 10.1007/s002770050229. Ann Hematol. 1996. PMID: 8890711 Clinical Trial.

6

High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.

Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Cancer. 1997 Jan 1;79(1):59-68. Cancer. 1997. PMID: 8988727

7

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W. Schleyer E, et al. Among authors: kern w. Leukemia. 1997 Dec;11 Suppl 5:S15-21. Leukemia. 1997. PMID: 9436933

8

Chronic systemic aspergillosis in a patient with acute myeloid leukemia.

Kern W, Braess J, Bertz H, Pott C, Schleyer E, Finke J, Rüchel R, Hiddemann W. Kern W, et al. Ann Hematol. 1998 Mar-Apr;76(3-4):175-7. doi: 10.1007/s002770050383. Ann Hematol. 1998. PMID: 9619736

9

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.

Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Leukemia. 1998 Jul;12(7):1049-55. doi: 10.1038/sj.leu.2401066. Leukemia. 1998. PMID: 9665189 Clinical Trial.

10

Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.

Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Cancer. 1998 Jul 15;83(2):291-301. Cancer. 1998. PMID: 9669812 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,211 results

Search Page

Filters